Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (201-210 of 264) with videos related to

Pageof 27
Sort By:
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Cancer Discovery|January 10, 2015
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growthLeili Ran, Inna Sirota, Zhen Cao, et al.
International Journal of Environmental Research and Public Health|May 9, 2014
Combination of a fast cleanup procedure and a DR-CALUX® bioassay for dioxin surveillance in Taiwanese soilsDing-Yan Lin, Yi-Pin Lee, Chiu-Ping Li, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Combined Inhibition of Gα<sub>q</sub> and MEK Enhances Therapeutic Efficacy in Uveal MelanomaTyler D Hitchman, Gabriella Bayshtok, Emilie Ceraudo, et al.
Ebiomedicine|January 25, 2019
Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradationYingyan Han, Peng Wu, Zhi Wang, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
NPJ Precision Oncology|January 2, 2023
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterationsDiana Mandelker, Antonio Marra, Nikita Mehta, et al.
The Journal of Clinical Investigation|July 24, 2020
ERG orchestrates chromatin interactions to drive prostate cell fate reprogrammingFei Li, Qiuyue Yuan, Wei Di, et al.
Journal of the American Chemical Society|March 17, 2020
Protecting Copper Oxidation State via Intermediate Confinement for Selective CO<sub>2</sub> Electroreduction to C<sub>2+</sub> FuelsPeng-Peng Yang, Xiao-Long Zhang, Fei-Yue Gao, et al.
Pageof 27

Showing results (201-210 of 264) with videos related to

Sort By:
Pageof 27
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Cancer Discovery|January 10, 2015
Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growthLeili Ran, Inna Sirota, Zhen Cao, et al.
International Journal of Environmental Research and Public Health|May 9, 2014
Combination of a fast cleanup procedure and a DR-CALUX® bioassay for dioxin surveillance in Taiwanese soilsDing-Yan Lin, Yi-Pin Lee, Chiu-Ping Li, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Combined Inhibition of Gα<sub>q</sub> and MEK Enhances Therapeutic Efficacy in Uveal MelanomaTyler D Hitchman, Gabriella Bayshtok, Emilie Ceraudo, et al.
Ebiomedicine|January 25, 2019
Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradationYingyan Han, Peng Wu, Zhi Wang, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
NPJ Precision Oncology|January 2, 2023
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterationsDiana Mandelker, Antonio Marra, Nikita Mehta, et al.
The Journal of Clinical Investigation|July 24, 2020
ERG orchestrates chromatin interactions to drive prostate cell fate reprogrammingFei Li, Qiuyue Yuan, Wei Di, et al.
Journal of the American Chemical Society|March 17, 2020
Protecting Copper Oxidation State via Intermediate Confinement for Selective CO<sub>2</sub> Electroreduction to C<sub>2+</sub> FuelsPeng-Peng Yang, Xiao-Long Zhang, Fei-Yue Gao, et al.
Pageof 27